300529.SZ SHZ
Jafron Biomedical Co.,Ltd.
1W: +0.0%
1M: -3.2%
3M: -5.8%
YTD: -24.9%
1Y: -34.5%
3Y: -29.1%
5Y: -79.9%
¥15.27 ($2.28)
+0.34 (+2.28%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.7B
+39.3% ▲
5Y CAGR: +13.3%
Gross Profit
$2.2B
+40.9% ▲
5Y CAGR: +11.8%
Operating Income
$1.0B
+92.2% ▲
5Y CAGR: +9.0%
Net Income
$820M
+87.9% ▲
5Y CAGR: +7.5%
EPS (Diluted)
$1.05
+90.9% ▲
5Y CAGR: +7.8%
EBITDA
$1.1B
+95.3% ▲
5Y CAGR: +12.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $2.0B | $2.7B | $2.5B | $1.9B | $2.7B |
| YoY Growth | +36.2% | +37.1% | -6.9% | -22.8% | +39.3% |
| Cost of Revenue | $288M | $402M | $440M | $391M | $520M |
| Gross Profit | $1.7B | $2.3B | $2.1B | $1.5B | $2.2B |
| Gross Margin | 85.2% | 85.0% | 82.3% | 79.7% | 80.6% |
| R&D Expenses | $81M | $174M | $254M | $245M | $240M |
| SG&A Expenses | $587M | $729M | $839M | $788M | $881M |
| Operating Expenses | $608M | $855M | $1.0B | $988M | $1.1B |
| Operating Income | $1.1B | $1.4B | $1.0B | $544M | $1.0B |
| Operating Margin | 54.0% | 53.0% | 41.3% | 28.3% | 39.0% |
| Interest Expense | $1M | $15M | $37M | $55M | $64M |
| Income Before Tax | $1.0B | $1.4B | $1.0B | $521M | $1.0B |
| Tax Expense | $159M | $211M | $136M | $95M | $193M |
| Net Income | $875M | $1.2B | $890M | $436M | $820M |
| Net Margin | 44.9% | 44.7% | 35.7% | 22.7% | 30.6% |
| EPS (Diluted) | $1.08 | $1.49 | $1.12 | $0.55 | $1.05 |
| EBITDA | $1.0B | $1.4B | $996M | $573M | $1.1B |
| Shares Outstanding | 810M | 803M | 798M | 794M | 767M |